In December last year, the Chinese NMPA approved amubarvimab/romlusevimab combination for Covid-19. Credit: NIAID / Flickr (Creative Commons).

TSB Therapeutics, a joint venture (JV) majority-owned by Brii Biosciences (Brii Bio), has entered a collaboration with China Resources Pharmaceutical Commercial Group (CR Pharma) for the commercialisation of an antibody therapy, amubarvimab/romlusevimab combination, for Covid-19 in China. 

Brii Bio developed the combination therapy in partnership with Tsinghua University and the 3rd People’s Hospital of Shenzhen. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Two non-competing SARS-CoV-2 monoclonal neutralising antibodies (mAbs), amubarvimab and romlusevimab, are obtained from convalesced Covid-19 patients.

Under the partnership, the parties will expedite the stockpiling, channel distribution and offer access to hospitals for the long-acting neutralising mAbs.

Furthermore, the companies are partnering to guarantee timely delivery of the therapy to support Covid-19 prevention and control efforts in the region. 

See Also:

They will also explore other new collaboration opportunities to facilitate extended access for the amubarvimab-romlusevimab combination in China.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In December last year, the National Medical Products Administration (NMPA) of China granted approval for the combination therapy for mild and normal Covid-19 in adults and paediatric individuals aged 12 to 17 years at increased risk for disease progression, including hospital admission or mortality. 

Earlier this month, the combination therapy was commercially launched in China.

Brii Bio Greater China president and general manager Rogers Luo said: “In 2019, Brii Bio started a strategic partnership with China Resources Group to jointly build an integrated industrial chain of life sciences.

“This strong and strategic partnership and unique operating model enables Brii Bio to rapidly expand access to our amubarvimab/romlusevimab combination to help more Covid-19 patients in China and we look forward to exploring in-depth collaborative efforts with China Resources Pharmaceutical Group down the line for the long-term benefit of patients and the healthcare community.”